Health ❯ Healthcare

Immunotherapy

Cancer Treatment Cancer Immunotherapy Checkpoint Inhibitors Cancer Vaccines Vaccine Development CAR-T Therapy mRNA Technology Clinical Trials Personalized Medicine Side Effects

First-in-Human SynKIR-110 Shows Safe Profile and Early Activity in Solid Tumors

The NK-inspired multi-chain receptor aims to curb T cell exhaustion by separating target sensing from activation.

Experimental Drug Elraglusib Extends Survival in Phase 2 Pancreatic Cancer Trial

Transgene Completes Phase 2 Randomization for Personalized Cancer Vaccine TG4050

Cadonilimab Plus Chemo Delivers Strong Phase 2 Signal in Frontline Endometrial Cancer

FDA Rejects Replimune’s Melanoma Virus Therapy Again for Insufficient Evidence

AstraZeneca’s Imfinzi–Imjudo Regimen Improves Progression-Free Survival in Liver Cancer Trial

Autolus Reports Q4 Loss, Reaffirms 2026 Sales Outlook for AUCATZYL, and Starts AUTO8 Trial

EU Drug Panel Backs Imdylltra for Relapsed Small Cell Lung Cancer

Enlivex Raises $21 Million, Buys 3 Billion RAIN Tokens at a Discount

Climate Change Is Extending Children’s Pollen Seasons in Italy, Driving a Diagnostic Overhaul

Ligand-Based OSM CAR-T Shows Preclinical Efficacy Against Osteosarcoma

EU Grants Conditional Approval for ImmunityBio’s Anktiva in BCG‑Unresponsive Bladder Cancer

DNA Origami Vaccine Scaffold Sharply Focuses HIV Immune Response in Preclinical Study

Morning Immunotherapy Boosts Survival in Lung Cancer Trial

Moderna–Merck Personalized Melanoma Vaccine Sustains 5-Year Benefit, Cutting Recurrence Risk by 49%

ImmunityBio Extends Rally to 52-Week High on Anktiva Sales, Saudi Approval and Trial Progress

First NHS Patient Completes Next‑Generation CAR‑T Therapy for Aggressive Leukaemia

FDA Issues Second Rejection of Atara’s EBV+ PTLD Therapy Tabelecleucel

Immune Atlas Sharpens Myeloma Risk Prediction as Dual-Target CAR T Counters BCMA Loss

Shorter, Chemo-Free Strategies Match or Beat Standard Care in Adult Leukemias at ASH